Under the deal, IFM will sell off IFM Tre and its assets, which focus on immune system drugs. IFM Tre has one drug, IFM-2427, in an early phase 1 trial and two other less-developed assets.
In buying three potential drugs, Novartis hopes to expand its pipeline of treatments for inflammatory disorders.
The deal is scheduled to close in the second quarter of this year.
More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy’s legal win expected to lower cost of opioid addiction treatment
